Log in to save to my catalogue

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named...

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2102921043

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program

About this item

Full title

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program

Publisher

England: Future Medicine Ltd

Journal title

Future oncology (London, England), 2018-11, Vol.14 (26), p.2691-2699

Language

English

Formats

Publication information

Publisher

England: Future Medicine Ltd

More information

Scope and Contents

Contents

To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results.
Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gle...

Alternative Titles

Full title

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2102921043

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2102921043

Other Identifiers

ISSN

1479-6694

E-ISSN

1744-8301

DOI

10.2217/fon-2018-0113

How to access this item